In view of addressing the global necessity of an effective vaccine in the SARS-CoV-2 pandemic, a plasmid DNA vaccine, expressing for the spike (S) protein and formulated in lipoplexes, was manufactured and tested for in vitro transfection and in vivo immunogenicity. Blank cationic liposomes of 130.9 ± 5.8 nm in size and with a zeta potential of +48 ± 12 mV were formulated using the thin-film layer rehydration method. Liposomes were complexed with pCMVkan-S at different N/P ratios. Ratios of 0.25:1 and 1:1 were selected according to their complex stability and controlled size compared to other ratios and tested in vitro for transfection studies and in vivo for immunogenicity. Both selected formulations showed enhanced neutralizing antibody responses compared to pCMVkan-S injected alone, as well as an increased T cell response. The titers observed were similar to those of intramuscular electroporation (IM-EP), which was set as an efficacy goal.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8402479PMC
http://dx.doi.org/10.3390/vaccines9080874DOI Listing

Publication Analysis

Top Keywords

dna vaccine
8
antibody responses
8
tested vitro
8
vitro transfection
8
vivo immunogenicity
8
vaccine administered
4
administered cationic
4
cationic lipoplexes
4
lipoplexes vivo
4
vivo electroporation
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!